Gilead Sciences

Summary

Pharmaceutical Company Intelligence Reports from Espicom Provide A Full Review of The Company's Activities Together with Five-Year Sales Forecasts for Its Key Products. The Company's Financial Performance Is Covered in-Depth, from Its Latest Results to A Complete Analysis of Its Latest Full Fiscal Year and An Outlook for The Future. A Section on Company Strategy Covers Mergers, Acquisitions and Divestitures, Key Agreements, Products and R&d. An Overview of Key Products and R&d Is Followed by A Comprehensive Review of The Company's Product Portfolio and Research and Development Pipeline by Therapeutic Area. in Addition, Supplementary Appendices Provide More in-Depth Information on Financials, Agreements and Corporate Events.

Contents

• Latest Results
• Executive Summary
• Introduction
• Current Financial Position
• Company Performance
• Business Segment Performance
• Geographic Segment Performance
  • Company Strategy
• Mergers, Acquisitions and Divestitures
• Key Agreements
• Employees
  • Product Performance Forecasts
  • Pipeline Analysis
  • Conclusions/Outlook
  • Therapeutic Area Focus
  • R&d Pipeline
  • Antiviral
  • Marketed Products
  • Atripla
  • Truvada
  • Viread
  • Others
• Hepatitis
  • Hepsera
  • R&d Projects
  • Elvitegravir (Gs 9137)
  • Gs 9131
• Hepatitis
  • Gs 9190
• Discontinued R&d Projects
  • Growth Forecast
• Hepatitis
  • Others
  • Marketed Products
  • Ambisome
  • Letairis
  • Others
  • R&d Projects
  • Aztreonam Lysine
  • Darusentan
  • Gs 59450
  • Gs 9310/11
  • Growth Forecast
• Appendix 1 - Financial Performance
• Appendix 2 - Key Corporate Events
• Appendix 3 - Key Agreements
  • 4aza Bioscience
  • Achillion Pharmaceuticals
  • Anadys Pharmaceuticals
  • Aspen Pharmacare
  • Astellas Pharma
  • Bristol-Myers Squibb
  • Dainippon Sumitomo Pharma
  • Diatos
  • Emory University/Royalty Pharma
  • Genelabs Technologies
  • Gladstone Institute of Virology and
  • Immunology
  • Glaxosmithkline
  • International Partnership for
  • Microbicides/Conrad
  • Japan Tobacco
  • Lg Life Sciences Ltd
  • Merck & Co
  • Novartis
  • Parion Sciences Inc
  • Roche
• Appendix 4 - Infrastructure
  • Research and Development Facilities
  • Manufacturing Facilities
• Appendix 5 - Key Pharmaceutical
  • Subsidiaries / Joint Ventures
  • Subsidiaries
  • Joint Ventures
• Index of Tables
  • Principal Operating Results
  • R&d Expenditure
  • Sales by Destination
  • Recent Product Approvals
  • Major Products, Therapeutic Areas and Sales
  • Major Hiv Products, 2007
  • Major Hepatitis Products, 2007
  • Major Other Area Products, 2006
• Index of Charts
  • R&d Expenditure, 2007
  • Sales by Destination
  • Sales of Top Five Products (2004a-2012e)
  • Top Selling Products, 2007
  • Atripla Sales (2006a-2012e)
  • Truvada Sales (2004a-2012e)
  • Viread Sales (2002a-2012e)
  • Gilead Sciences
  • Hepsera Sales (2002a-2012e)
  • Gs 9137 Sales (2009a-2013e)
  • Hiv Product Portfolio Forecast (2006a-2011e)
  • Ambisome Sales (2001a-2011e)
  • Aztreonam Sales (2008e-2012e)
  • Darusentan Sales (2009e-2013e)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&d Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity